MRVI250516C2000
- 0.39
- 0.000.00%
Maravai LifeSciences Newsroom
Earnings Preview: MRVI to Report Financial Results Post-market on May 12
Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
MRVI Investors Have Opportunity to Lead Maravai Lifesciences Holdings, Inc. Securities Fraud Lawsuit
Express News | Maravai LifeSciences Q1 Revenue USD 56.6 Million Vs. IBES Estimate USD 44.1 Million
Maravai LifeSciences Holdings, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $7
New Analyst Forecast: $MRVI Given $5.0 Price Target
Stifel Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Opthea Limited (OtherCKDXF), Outset Medical (OM) and Maravai Lifesciences Holdings (MRVI)
Is Maravai LifeSciences Holdings, Inc. (MRVI) the Top Stock to Buy According to 12 West Capital Management?
Maravai LifeSciences Is Maintained at Equal-Weight by Morgan Stanley
Trump Media & Technology Group, BitFuFu, Mobileye Global And Other Big Stocks Moving Higher On Tuesday
RBC Capital Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Morgan Stanley Maintains Maravai LifeSciences(MRVI.US) With Hold Rating, Cuts Target Price to $5
Stifel Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $5
UBS Maintains Maravai LifeSciences(MRVI.US) With Hold Rating, Cuts Target Price to $2.5
UBS Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $2.5
Maravai LifeSciences Analyst Ratings
Strategic Acquisitions and Market Expansion Drive Buy Rating for Maravai Lifesciences Holdings
Maravai Lifesciences Price Target Lowered to $5 From $10 at Stifel